Related Experiment Video
Updated: Aug 4, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer
Leena Kumari1, Iman Ehsan1, Arunima Mondal2
1Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Abstract:
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers diagnosed worldwide, yet managing it is still challenging. The epidermal growth factor receptor (EGFR) exhibits aberrant signalling in a wide range of human cancers, and it is reported to overexpress in most NSCLC cases. The monoclonal antibody [Cetuximab (Cet)] was conjugated onto the surface of the poly (lactide-co-glycolide) (PLGA) nanoparticles which were loaded with docetaxel (DTX) for the development of targeted therapy against lung cancer. This site-specific delivery system exhibited an enhanced cellular uptake in lung cancer cells which overexpress EGFR (A549 and NCI-H23). The nanoparticles also showed better therapeutic effectiveness against NSCLC cells, as evidenced by reduced IC50 values, cell cycle arrest at the G2/M phase, and increased apoptosis. The improved efficacy and in vivo tolerance of Cet-DTX NPs were demonstrated in benzo(a)pyrene (BaP)-induced lung cancer mice model. Histopathological analysis showed that intravenous injection of Cet-DTX NP to mice carrying lung cancer greatly reduced tumour development and proliferation. Comparing Cet-DTX NP to free drug and unconjugated nanoparticles, it also had negligible side effects and improved survival rates. Therefore, Cet-DTX NPs present a promising active targeting carrier for lung tumour-NSCLC-selective treatment.
Insights
Targeted nanoparticles carrying docetaxel and cetuximab show promise for non-small cell lung cancer (NSCLC) treatment. This novel drug delivery system enhances efficacy and reduces side effects in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) is a prevalent and challenging malignancy.
- Epidermal growth factor receptor (EGFR) is frequently overexpressed in NSCLC, presenting a therapeutic target.
- Current NSCLC management strategies require improved targeted therapies.
Purpose of the Study:
- To develop and evaluate a targeted nanoparticle system for NSCLC treatment.
- To conjugate the monoclonal antibody Cetuximab (Cet) onto docetaxel (DTX)-loaded poly (lactide-co-glycolide) (PLGA) nanoparticles (NPs).
- To assess the efficacy and safety of Cet-DTX NPs in preclinical NSCLC models.
Main Methods:
- Cetuximab was conjugated to PLGA nanoparticles loaded with docetaxel.
- Cellular uptake studies were performed on EGFR-overexpressing lung cancer cell lines (A549 and NCI-H23).
- In vitro efficacy was assessed by IC50 values, cell cycle analysis, and apoptosis assays.
- In vivo studies utilized a benzo(a)pyrene-induced lung cancer mouse model to evaluate therapeutic effectiveness and tolerance.
Main Results:
- Cet-DTX NPs demonstrated enhanced cellular uptake in EGFR-overexpressing lung cancer cells.
- In vitro studies showed reduced IC50 values, G2/M cell cycle arrest, and increased apoptosis.
- In vivo administration of Cet-DTX NPs significantly reduced tumour development and proliferation in mice.
- Cet-DTX NPs exhibited improved tolerance, negligible side effects, and enhanced survival rates compared to free drug and unconjugated nanoparticles.
Conclusions:
- Cet-DTX NPs represent a promising active targeting drug delivery system for NSCLC.
- This targeted approach offers enhanced therapeutic efficacy and improved safety profile for lung cancer treatment.
- The developed nanoparticles show potential for selective treatment of NSCLC tumors.
More Related Videos
05:55Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
Published on: September 18, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
